The IPSS-R has prognostic impact in untreated patients with MDS del(5q)

Myelodysplastic syndromes (MDS) are known to occur as an insufficiency of the bone marrow to produce a satisfactory amount of mature and functioning blood cells, resulting in cytopenia, especially in anemia in most cases, and dysplasia. MDS del(5q) is a subtype presenting with a deletion in the long arm of chromosome 5, which predominantly occurs in women and clinically presents with prominent anemia, dysmegakaryopoesis, often thrombocytosis and low blast counts in the bone marrow. As transformation rates into acute myeloid leukemia (AML) are relatively low and patients tend to suffer from mild symptoms compared to other subtypes, MDS del(5q) is regarded as a MDS with a good prognosis.

Source: Leukemia Research - July 23, 2018 Category: Hematology Authors: J. Kaivers, M. Lauseker, B. Hildebrandt, P. Fenaux, M. Pfeilst öcker, P. Valent, U. Platzbecker, R. Latagliata, E.N. Oliva, B. Xicoy, K. Götze, C. Ganster, D. Haase, G. Bug, A. Kündgen, N. Gattermann, R. Haas, U. Germing Source Type: research